(Q36858857)

16 August 2017

1 reference

title

Autotransplant conditioning regimens for aggressive lymphoma: are we on the right road? (English)

1 reference

16 August 2017

1 reference

Fernandez HF

1

1 reference

16 August 2017

Escalón MP

series ordinal

2

1 reference

16 August 2017

Pereira D

series ordinal

3

1 reference

16 August 2017

Lazarus HM

series ordinal

4

1 reference

16 August 2017

language of work or name

English

0 references

publication date

25 June 2007

1 reference

Bone Marrow Transplantation

16 August 2017

published in

1 reference

16 August 2017

volume

40

1 reference

16 August 2017

issue

6

1 reference

16 August 2017

page(s)

505-513

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1705744

16 August 2017

exact match

0 references

cites work

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705744

7 January 2021

Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705744

7 January 2021

Outcome in Patients With Myelodysplastic Syndrome After Autologous Bone Marrow Transplantation for Non-Hodgkin's Lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705744

7 January 2021

Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT. EBMT Lymphoma and Late Effects Working Parties. European Group for Blood and Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705744

7 January 2021

BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705744

7 January 2021

Busulfan and cyclophosphamide (BU/CY2) as preparative regimen for patients with lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705744

7 January 2021

Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705744

7 January 2021

Intensified preparative regimens and autologous transplantation in refractory or relapsed intermediate grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705744

7 January 2021

Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens--a Southwest Oncology Group trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705744

7 January 2021

High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortality

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705744

7 January 2021

High-Dose Chemotherapy and Autologous Bone Marrow Transplantation Compared with MACOP-B in Aggressive B-Cell Lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705744

7 January 2021

Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705744

7 January 2021

The role of molecular monitoring in autotransplantation for non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705744

7 January 2021

High-dose therapy supported with immunomagnetic purged autologous bone marrow in high-grade B cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705744

7 January 2021

Randomised comparison of two B-cell purging protocols for patients with B-cell non-Hodgkin lymphoma: in vivo purging with rituximab versus ex vivo purging with CliniMACS CD34 cell enrichment device

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705744

7 January 2021

Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin's lymphoma: a case-matched comparison with unpurged cases by the European Blood and Marrow Transplant Lymphoma Registry

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705744

7 January 2021

Effects of Pretransplantation Treatment With Rituximab on Outcomes of Autologous Stem-Cell Transplantation for Non-Hodgkin's Lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705744

7 January 2021

Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705744

7 January 2021

Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705744

7 January 2021

Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705744

7 January 2021

Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705744

7 January 2021

Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705744

7 January 2021

Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705744

7 January 2021

A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705744

7 January 2021

Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705744

7 January 2021

Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705744

7 January 2021

VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705744

7 January 2021

Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705744

7 January 2021

Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705744

7 January 2021

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705744

7 January 2021

Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705744

7 January 2021

HiC-COM: a 2-month intensive chemotherapy regimen for children with stage III and IV Burkitt's lymphoma and B-cell acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705744

7 January 2021

Adult Burkitt's and Burkitt-like non-Hodgkin's lymphoma--outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantat

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705744

7 January 2021

High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Bl

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705744

7 January 2021

A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705744

7 January 2021

High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705744

7 January 2021

High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705744

7 January 2021

Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705744

7 January 2021

Gemcitabine, vinorelbine and prednisone for refractory or relapsed aggressive lymphoma, results of a phase II single center study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705744

7 January 2021

Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705744

7 January 2021

Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705744

7 January 2021

Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705744

7 January 2021

Does autologous transplantation directly increase the risk of secondary leukemia in lymphoma patients?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705744

7 January 2021

Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705744

7 January 2021

The polymorphic human glutathione transferase T1-1, the most efficient glutathione transferase in the denitrosation and inactivation of the anticancer drug 1,3-bis(2-chloroethyl)-1-nitrosourea

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705744

7 January 2021

Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705744

7 January 2021

Mucosal injury in patients undergoing hematopoietic progenitor cell transplantation: new approaches to prophylaxis and treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705744

7 January 2021

Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705744

7 January 2021

Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705744

7 January 2021

Immunotherapy with rituximab/interleukin-2 after autologous stem cell transplantation as treatment for CD20+ non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705744

7 January 2021

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705744

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1705744

1 reference

16 August 2017

1 reference